Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia)
- Determine the objective response in patients with Waldenstrom's macroglobulinemia
treated with alemtuzumab.
- Determine the time to treatment failure in patients treated with this drug.
- Determine the toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive alemtuzumab IV over 2 hours on days 1, 3, and 5 of weeks 1-6 (course 1) in
the absence of disease progression or unacceptable toxicity. Patients with a complete
response undergo observation. Patients with stable disease or a minor or partial response
receive an additional course of alemtuzumab, administered as in course 1, on weeks 7-12.
Patients are followed every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 13-27 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Jennifer Gansert, MD, PhD
Jonsson Comprehensive Cancer Center
United States: Federal Government
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Cleveland Clinic Taussig Cancer Center||Cleveland, Ohio 44195|
|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute||Boston, Massachusetts 02115|
|Herbert Irving Comprehensive Cancer Center at Columbia University||New York, New York 10032|
|Long Island Jewish Medical Center||New Hyde Park, New York 11040|
|Greenebaum Cancer Center at University of Maryland Medical Center||Baltimore, Maryland 21201|
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|
|Robert H. Lurie Comprehensive Cancer Center at Northwestern University||Chicago, Illinois 60611|
|Rocky Mountain Cancer Centers - Denver Midtown||Denver, Colorado 80218|